Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume

Pharming Group (NASDAQ:PHARGet Free Report) shares saw unusually-strong trading volume on Tuesday . Approximately 3,026 shares were traded during trading, an increase of 139% from the previous session’s volume of 1,268 shares.The stock last traded at $12.15 and had previously closed at $12.90.

Pharming Group Price Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.50 and a current ratio of 4.29. The business’s 50 day moving average is $11.74 and its 200 day moving average is $11.98.

Pharming Group (NASDAQ:PHARGet Free Report) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.08). Pharming Group had a negative net margin of 10.08% and a negative return on equity of 10.25%. The company had revenue of $66.66 million during the quarter, compared to analyst estimates of $61.67 million. On average, sell-side analysts anticipate that Pharming Group will post -0.03 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC bought a new position in shares of Pharming Group (NASDAQ:PHARFree Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,715 shares of the company’s stock, valued at approximately $134,000. Institutional investors own 0.04% of the company’s stock.

About Pharming Group

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.

See Also

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.